Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.

Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.

Abstract: A compound of formula (I): (I) and its conjugates.

Abstract: A conjugate comprising the following topoisomerase inhibitor derivative (A*): with a linker for connecting to a Ligand Unit, wherein the linker is attached in a cleavable manner to the amino residue. The Ligand Unit is preferably an antibody. Also provided is A* with the linking unit attached, and intermediates for their synthesis, as well as the released warhead.

Abstract: A compound which is either A: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: The disclosure provides conjugates of an isolated humanized anti-CD22 antibody and PBD dimers.

Abstract: Conjugates of an antibody that binds to CD19 with PBD dimers.

Abstract: The present disclosure relates to the use of antibody-drug conjugates (ADCs) comprising pyrrolobenzodiazepine (PBD) dimers and anti-CD25 antibodies for use in treating disorders characterized by the presence of CD25+ve cells.

Abstract: A conjugate of formula I, wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.

Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.

Abstract: Conjugates of an antibody that binds to PSMA with PBD dimers.

Abstract: A conjugate of formula (I) wherein Ab is a modified antibody having at least one free conjugation site on each heavy chain.

Abstract: Conjugates of an isolated humanized, anti-CD22 antibody with PBD dimers.

Abstract: Conjugates of an antibody that binds to CD25 with PBD dimers.

Abstract: A conjugate of formula (I): L-(DL)p (I) wherein L is a Ligand unit, D is a Drug Linker unit of formula (II) wherein p is an integer of from 1 to 20.

Abstract: There is described a multi-unit dose dry powder medicament delivery device comprising: a first element comprising a single use nozzle located in a body which is at least partially lined with an inner member, said inner sleeve comprising an airway and a cartridge seat; and a second element adapted to be releasably attached to the first element, said second element comprising an actuator provided with an air source and a valve.

Abstract: This invention relates to peptidomimetic linkers and anti-body drug conjugates thereof pharmaceutical compositions containing them, and to their use in therapy for the prevention treatment of cancer.

Abstract: A compound which is either A: or B: and salts and solvates thereof, as well as their conjugates with a cell-binding agent.

Abstract: A compound of formula I and salts and solvates thereof, wherein: R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; where R and R? are independently selected from optionally substituted C1-12 alkyl, C3-20 heterocyclyl and C5-20 aryl groups; R7 is selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, nitro, Me3Sn and halo; R? is a C3-12 alkylene group, which chain may be interrupted by one or more heteroatoms, e.g. O, S, NRN2 (where RN2 is H or C1-4 alkyl), and/or aromatic rings, e.g. benzene or pyridine; Y and Y? are selected from O, S, or NH; R6, R7, R9 are selected from the same groups as R6, R7 and R9 respectively; R11b is selected from OH, ORA, where RA is C1-4 alkyl; and RL is a linker for connection to a cell binding agent.

Abstract: Conjugate compounds of formula (A): wherein: R2 is where R36a and R36b are independently selected from H, F, C1-4 saturated alkyl, C2-3 alkenyl, which alkyl and alkenyl groups are optionally substituted by a group selected from C1-4 alkyl amido and C1-4 alkyl ester; or, when one of R36a and R36b is H, the other is selected from nitrile and a C1-4 alkyl ester; R6 and R9 are independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; R7 is independently selected from H, R, OH, OR, SH, SR, NH2, NHR, NRR?, NO2, Me3Sn and halo; Y is selected from formulae A1, A2, A3, A4, A5 and A6: L is a linker connected to a cell binding agent; CBA is the cell binding agent; n is an integer selected in the range of 0 to 48; RA4 is a C1-6 alkylene group; either (a) R10 is H, and R11 is OH, ORA, where RA is C1-4 alkyl; or (b) R10 and R11 form a nitrogen-carbon double bond between the nitrogen and carbon atoms to which they are bound; or (c) R10 is H and R11 is OSOzM, wher